Profile data is unavailable for this security.
About the company
Fate Therapeutics, Inc. is a clinical-stage biopharmaceutical company. The Company is dedicated to bringing a pipeline of induced pluripotent stem cell (iPSC)-derived cellular immunotherapies to patients with cancer and autoimmune disorders. Its proprietary induced pluripotent stem cells (iPSC) product platform combines multiplexed-engineering of human iPSCs with single-cell selection to create clonal master iPSC lines. The Company’s platform is designed to overcome numerous limitations associated with the manufacture of cell therapies using patient- or donor-sourced cells. Utilizing its proprietary iPSC product platform, it is advancing off-the-shelf, multiplexed-engineered natural killer (NK) cell and T-cell product candidates which are selectively designed, incorporate novel synthetic controls of cell function. Its pipeline of iPSC-derived, chimeric antigen receptor (CAR)-targeted NK cell and T-cell product candidates include FT819, FT522, FT576, FT825, FT819, FT522, and others.
- Revenue in USD (TTM)12.32m
- Net income in USD-175.72m
- Incorporated2007
- Employees181.00
- LocationFate Therapeutics Inc12278 Scripps Summit DriveSAN DIEGO 92131United StatesUSA
- Phone+1 (858) 875-1803
- Fax+1 (302) 636-5454
- Websitehttps://fatetherapeutics.com/
Peer analysis
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
GH Research PLC | -100.00bn | -100.00bn | 415.70m | 49.00 | -- | 2.09 | -- | -- | -- | -- | -- | 3.82 | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | 0.0038 | -- | -- | -- | -58.47 | -- | -- | -- |
iTeos Therapeutics Inc | 35.00m | -108.14m | 423.29m | 157.00 | -- | 0.6376 | -- | 12.09 | -3.00 | -3.00 | 0.9517 | 18.18 | 0.0481 | -- | 1.52 | 222,929.90 | -14.86 | 5.84 | -15.55 | 7.02 | -- | -- | -308.96 | 22.09 | -- | -- | 0.00 | 0.00 | -95.29 | -- | -216.54 | -- | 68.45 | -- |
Instil Bio Inc | 0.00 | -119.58m | 429.91m | 49.00 | -- | 2.20 | -- | -- | -18.39 | -18.39 | 0.00 | 29.98 | 0.00 | -- | -- | 0.00 | -34.04 | -- | -35.48 | -- | -- | -- | -- | -- | -- | -- | 0.2958 | -- | -- | -- | 30.06 | -- | -- | -- |
Grail Inc | 109.74m | -2.88bn | 431.89m | 1.37k | -- | 0.1603 | -- | 3.94 | -99.94 | -99.94 | 3.91 | 86.80 | -- | -- | -- | 81,894.77 | -- | -47.45 | -- | -48.55 | 44.06 | -- | -2,627.35 | -5,118.86 | -- | -- | 0.00 | -- | 67.61 | -- | 72.85 | -- | -4.22 | -- |
Larimar Therapeutics Inc | 0.00 | -58.34m | 437.08m | 42.00 | -- | 2.07 | -- | -- | -1.11 | -1.11 | 0.00 | 3.31 | 0.00 | -- | -- | 0.00 | -33.44 | -42.22 | -36.41 | -47.14 | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | -4.51 | -- | 8.71 | -- |
Taysha Gene Therapies Inc | 12.87m | -114.34m | 440.63m | 52.00 | -- | 3.98 | -- | 34.23 | -0.8987 | -0.8987 | 0.0643 | 0.5406 | 0.0913 | -- | -- | 247,557.70 | -81.11 | -- | -116.01 | -- | -- | -- | -888.18 | -- | -- | -- | 0.2598 | -- | 517.55 | -- | 32.80 | -- | -- | -- |
Fate Therapeutics Inc | 12.32m | -175.72m | 441.85m | 181.00 | -- | 1.11 | -- | 35.87 | -1.71 | -1.71 | 0.1185 | 3.49 | 0.0221 | -- | 6.35 | 68,049.73 | -31.56 | -31.82 | -33.99 | -36.05 | -- | -- | -1,426.67 | -359.33 | -- | -- | 0.00 | -- | -34.03 | 68.05 | 42.88 | -- | 21.72 | -- |
C4 Therapeutics Inc | 29.38m | -107.87m | 442.37m | 145.00 | -- | 1.78 | -- | 15.06 | -1.90 | -1.90 | 0.4944 | 3.59 | 0.0777 | -- | 26.77 | 202,606.90 | -28.53 | -25.91 | -33.00 | -29.45 | -- | -- | -367.17 | -292.35 | -- | -- | 0.00 | -- | -33.25 | 1.40 | -3.37 | -- | -8.68 | -- |
Absci Corp | 3.25m | -92.26m | 451.95m | 155.00 | -- | 2.04 | -- | 139.06 | -0.9331 | -0.9331 | 0.0327 | 1.95 | 0.0128 | -- | 2.03 | 20,967.74 | -36.20 | -- | -40.23 | -- | -- | -- | -2,838.89 | -- | -- | -129.46 | 0.0284 | -- | -0.5046 | -- | -5.40 | -- | -- | -- |
ACELYRIN Inc | 0.00 | -299.80m | 459.12m | 130.00 | -- | 0.8061 | -- | -- | -3.06 | -3.06 | 0.00 | 5.71 | 0.00 | -- | -- | 0.00 | -40.33 | -- | -43.71 | -- | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | -489.21 | -- | -- | -- |
SAGE Therapeutics Inc | 97.24m | -445.67m | 463.37m | 487.00 | -- | 0.7359 | -- | 4.77 | -7.41 | -7.41 | 1.62 | 10.31 | 0.1093 | -- | 6.75 | 199,679.70 | -50.09 | -21.88 | -55.24 | -23.30 | 95.47 | 99.63 | -458.30 | -131.50 | -- | -- | 0.00 | -- | 1,024.84 | -0.8606 | -1.63 | -- | -28.01 | -- |
Verve Therapeutics Inc | 20.65m | -192.65m | 466.28m | 255.00 | -- | 0.8531 | -- | 22.58 | -2.59 | -2.59 | 0.275 | 6.46 | 0.032 | -- | 8.05 | 80,972.55 | -29.87 | -- | -31.67 | -- | -- | -- | -933.03 | -- | -- | -- | 0.00 | -- | 505.77 | -- | -27.12 | -- | -- | -- |
Anavex Life Sciences Corp | 0.00 | -41.53m | 466.38m | 40.00 | -- | 3.59 | -- | -- | -0.5012 | -0.5012 | 0.00 | 1.53 | 0.00 | -- | -- | 0.00 | -27.75 | -40.04 | -30.03 | -43.97 | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | 0.9857 | -- | -- | -- |
Aura Biosciences Inc | 0.00 | -80.69m | 473.74m | 88.00 | -- | 2.47 | -- | -- | -1.79 | -1.79 | 0.00 | 3.86 | 0.00 | -- | -- | 0.00 | -39.26 | -- | -41.21 | -- | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | -30.03 | -- | -- | -- |
Contineum Therapeutics Inc | -100.00bn | -100.00bn | 475.62m | 31.00 | -- | 2.19 | -- | -- | -- | -- | -- | 8.46 | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | 193.68 | -- | -- | -- |
Holder | Shares | % Held |
---|---|---|
Redmile Group LLCas of 30 Jun 2024 | 13.17m | 11.56% |
The Vanguard Group, Inc.as of 30 Jun 2024 | 10.42m | 9.15% |
BlackRock Fund Advisorsas of 30 Jun 2024 | 7.82m | 6.87% |
Deep Track Capital LPas of 30 Jun 2024 | 5.57m | 4.89% |
SSgA Funds Management, Inc.as of 30 Jun 2024 | 5.34m | 4.69% |
Bellevue Asset Management AGas of 30 Jun 2024 | 4.84m | 4.25% |
Citadel Advisors LLCas of 30 Jun 2024 | 4.23m | 3.71% |
D. E. Shaw & Co. LPas of 30 Jun 2024 | 4.08m | 3.58% |
Baker Bros. Advisors LPas of 30 Jun 2024 | 3.00m | 2.63% |
Morgan Stanley & Co. LLCas of 30 Jun 2024 | 2.89m | 2.54% |